Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/23317
Title: Evaluation of Galectin-3 as a Novel Biomarker for Chagas Cardiomyopathy
Authors: Rabelo, Márcia Maria Noya
Larocca, Ticiana Ferreira
Macêdo, Carolina Thé
Torreão, Jorge Andion
Souza, Bruno Solano de Freitas
Vasconcelos, Juliana Fraga
Souza, Luciana Estrella
Silva, Agnaluce Moreira
Santos, Ricardo Ribeiro dos
Correia, Luís Claudio Lemos
Soares, Milena Botelho Pereira
Affilliation: Hospital São Rafael. Department of Cardiology. Salvador, BA, Brasil / Escola Bahiana de Medicina e Saúde Pública. Salvador, BA, Brasil
Hospital São Rafael. Department of Cardiology. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Center for Biotechnology and Cell Therapy. Salvador, BA, Brasil
Hospital São Rafael. Department of Cardiology. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Center for Biotechnology and Cell Therapy. Salvador, BA, Brasil
Hospital São Rafael. Department of Cardiology. Salvador, BA, Brasil / Escola Bahiana de Medicina e Saúde Pública. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Center for Biotechnology and Cell Therapy. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Center for Biotechnology and Cell Therapy. Salvador, BA, Brasil
Hospital São Rafael. Clinical Diagnostics Laboratory. Salvador, BA, Brasil
Hospital São Rafael. Clinical Diagnostics Laboratory. Salvador, BA, Brasil
Center for Biotechnology and Cell Therapy. Salvador, BA, Brasil
Hospital São Rafael. Department of Cardiology. Salvador, BA, Brasil / Escola Bahiana de Medicina e Saúde Pública. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Center for Biotechnology and Cell Therapy. Salvador, BA, Brasil
Abstract: Chagas cardiomyopathy has worse long-term outcomes than other cardiomyopathies. A biomarker strategy to refer subjects for noninvasive cardiac imaging may help in the early identification of cardiac damage in subjects with Chagas disease. Galectin-3 (Gal-3) is a mediator of cardiac fibrosis shown to be upregulated in animal models of decompensated heart failure. Here we assessed the correlation of Gal-3 with myocardial fibrosis in patients with Chagas disease. Methods: This study comprised 61 subjects with Chagas disease. All subjects underwent clinical assessments, Doppler echocardiography and magnetic resonance imaging. Plasmatic Gal-3 was determined by ELISA. Results: Delayed enhancement (DE) was identified in 37 of 61 subjects (64%). The total amount of myocardial fibrosis was 9.4% [interquartile interval (IQI): 2.4–18.4]. No differences were observed in Gal-3 concentration according to the presence or absence of myocardial fibrosis, with a median Gal-3 concentration of 11.7 ng/ml (IQI: 9.4–15) in subjects with DE versus 12.9 ng/ml (IQI: 9.2–14) in subjects without DE (p = 0.18). No correlation was found between myocardial fibrosis and Gal- 3 concentration (r = 0.098; p = 0.47). Conclusions: There is no correlation between the degree of myocardial fibrosis and the concentration of Gal-3 in subjects with Chagas disease
Keywords: Chagas disease
Biomarkers
Galectin-3
keywords: Doença de Chagas
Biomarcadores
Galectina-3
Issue Date: 2017
Publisher: Karger Publishers
Citation: RABELO, M. M. N. et al. Evaluation of galectin-3 as a novel biomarker for Chagas Cardiomyopathy. Cardiology, v. 136, p. 33–39, 2017.
DOI: 10.1159/000447529
ISSN: 0008-6312
Copyright: open access
Appears in Collections:BA - IGM - Artigos de Periódicos

Files in This Item:
File Description SizeFormat 
Rabelo MMN Evaluation of galectin-3....pdf137.33 kBAdobe PDFView/Open


FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.